Buprenorphine
Buprenorphine is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Buprenorphine; Generic name: BUPRENORPHINE; Drug class: Partial Opioid Agonist [EPC].
| Brand name | Buprenorphine |
|---|---|
| Generic name | BUPRENORPHINE |
| Drug class | Partial Opioid Agonist [EPC] |
| Manufacturer | INGENUS PHARMACEUTICALS, LLC |
| Used for | 1 INDICATIONS AND USAGE Buprenorphine transdermal system is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate release opioids. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions ( 5.1 )] , reserve opioid analgesics, including buprenorphine transdermal system, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pai |
| Dosage | 2 DOSAGE AND ADMINISTRATION Buprenorphine transdermal system should be prescribed only by healthcare professionals who are knowledgeable about the use of extended-release/long-acting opioids and how to mitigate the associated risks. ( 2.1 ) Buprenorphine transdermal system doses of 7.5, 10, 15, and 20 mcg/hour are only for use in patients receiving, for one week or longer, daily opioid doses up to 80 mg/day of oral morphine or an equianalgesic dose of another opioid. ( 2.1 ) Use the lowest effec |
| Warnings | WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BUPRENORPHINE TRANSDERMAL SYSTEM Addiction, Abuse, and Misuse Because the use of buprenorphine transdermal system exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.1 )]. Life-Threatening Respiratory |
| Active ingredient(s) | BUPRENORPHINE |
| Route | TRANSDERMAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=186e3be6-8bc0-4bb9-96f5-429d53632f45 |